Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Prostatic Neoplasms 958Urinary Bladder Neoplasms 264Carcinoma, Renal Cell 251Kidney Neoplasms 146Carcinoma, Transitional Cell 130Breast Neoplasms 128Neoplasms 122Colorectal Neoplasms 97Ovarian Neoplasms 91Melanoma 86Carcinoma, Non-Small-Cell Lung 84Lung Neoplasms 81Neoplasm Metastasis 79Pancreatic Neoplasms 68Non-Muscle Invasive Bladder Neoplasms 68Uterine Cervical Neoplasms 58Stomach Neoplasms 55Head and Neck Neoplasms 51Squamous Cell Carcinoma of Head and Neck 47Endometrial Neoplasms 47Adenocarcinoma 46Esophageal Neoplasms 44Testicular Neoplasms 42Sarcoma 41Carcinoma, Hepatocellular 41Disease 33Triple Negative Breast Neoplasms 32Liver Neoplasms 30Colonic Neoplasms 29Metastatic Castration-resistant Prostate Cancer 25

Interventions

enzalutamide 1apalutamide 1Prednisolone 1Poly(ADP-ribose) Polymerase Inhibitors 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoadjuvant Therapy × Genitourinary × Clear all
NCT05406999 2022-08-16

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Recruiting
900 enrolled
Genitourinary

Neoadjuvant Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡